MX2017000613A - Indoles funcionalizados y sustituidos como agentes anticancer. - Google Patents
Indoles funcionalizados y sustituidos como agentes anticancer.Info
- Publication number
- MX2017000613A MX2017000613A MX2017000613A MX2017000613A MX2017000613A MX 2017000613 A MX2017000613 A MX 2017000613A MX 2017000613 A MX2017000613 A MX 2017000613A MX 2017000613 A MX2017000613 A MX 2017000613A MX 2017000613 A MX2017000613 A MX 2017000613A
- Authority
- MX
- Mexico
- Prior art keywords
- functionalised
- cancer agents
- substituted indoles
- compounds
- disease
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos antitropomiosina, procesos para su preparación, y métodos para tratar o prevenir una enfermedad o trastorno, como una enfermedad proliferativa (de preferencia cáncer), usando compuestos de la invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462025207P | 2014-07-16 | 2014-07-16 | |
PCT/AU2015/050400 WO2016008011A1 (en) | 2014-07-16 | 2015-07-16 | Functionalised and substituted indoles as anti-cancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017000613A true MX2017000613A (es) | 2017-04-27 |
Family
ID=55077744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000613A MX2017000613A (es) | 2014-07-16 | 2015-07-16 | Indoles funcionalizados y sustituidos como agentes anticancer. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20170152226A1 (es) |
EP (1) | EP3169683A4 (es) |
JP (1) | JP2017520612A (es) |
KR (1) | KR20170031097A (es) |
CN (1) | CN106661005A (es) |
AU (3) | AU2015227454B2 (es) |
BR (1) | BR112017000714A2 (es) |
CA (1) | CA2952557A1 (es) |
CL (1) | CL2017000054A1 (es) |
CO (1) | CO2017000065A2 (es) |
IL (1) | IL250074A0 (es) |
MX (1) | MX2017000613A (es) |
PH (1) | PH12016502607A1 (es) |
RU (1) | RU2017104856A (es) |
SG (1) | SG11201610195UA (es) |
WO (1) | WO2016008011A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016538309A (ja) * | 2013-11-25 | 2016-12-08 | ノボゲン リミテッドNovogen Ltd | 抗がん剤としての官能化及び置換インドール |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
KR101862765B1 (ko) | 2017-04-21 | 2018-05-30 | 한국화학연구원 | N-아릴사이클릭아민 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
SG11202001684PA (en) | 2017-10-06 | 2020-03-30 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
WO2019192506A1 (en) * | 2018-04-03 | 2019-10-10 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
WO2020072964A1 (en) | 2018-10-05 | 2020-04-09 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN110128415B (zh) * | 2019-05-31 | 2022-03-25 | 沈阳药科大学 | 用作免疫调节剂的吲哚啉类化合物及其制备方法 |
CN110229091B (zh) * | 2019-06-21 | 2022-11-22 | 天津科技大学 | 具有白三烯a4水解酶抑制作用的1,5-二取代吲哚衍生物及应用 |
CN113121429B (zh) * | 2020-01-15 | 2024-04-26 | 鲁南制药集团股份有限公司 | 一种c-Met激酶抑制剂及其制备方法和应用 |
CN113149897B (zh) * | 2021-03-24 | 2023-10-31 | 福建省中科生物股份有限公司 | 一种2,6-取代-4-氧基萜酚吡啶类化合物及其制备方法和用途 |
EP4392406A1 (en) * | 2021-09-30 | 2024-07-03 | Trobio Therapeutics Pty Ltd | Substituted indole compounds and the use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024440A1 (en) * | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
WO2001025220A1 (en) * | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
US6881737B2 (en) * | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
PL2114878T3 (pl) * | 2007-01-08 | 2011-05-31 | Suven Life Sciences Ltd | Związki 5-(heterocyklilo)alkilo-N-(arylosulfonylo)indolowe i ich zastosowanie jako ligandy 5-HT6 |
PT2488486T (pt) * | 2009-10-13 | 2019-11-05 | Ligand Pharm Inc | Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos |
US9145412B2 (en) * | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
JP2016538309A (ja) * | 2013-11-25 | 2016-12-08 | ノボゲン リミテッドNovogen Ltd | 抗がん剤としての官能化及び置換インドール |
-
2015
- 2015-07-16 EP EP15822783.5A patent/EP3169683A4/en not_active Withdrawn
- 2015-07-16 US US15/323,694 patent/US20170152226A1/en not_active Abandoned
- 2015-07-16 MX MX2017000613A patent/MX2017000613A/es unknown
- 2015-07-16 KR KR1020167035249A patent/KR20170031097A/ko unknown
- 2015-07-16 SG SG11201610195UA patent/SG11201610195UA/en unknown
- 2015-07-16 CA CA2952557A patent/CA2952557A1/en not_active Abandoned
- 2015-07-16 BR BR112017000714-2A patent/BR112017000714A2/pt not_active Application Discontinuation
- 2015-07-16 WO PCT/AU2015/050400 patent/WO2016008011A1/en active Application Filing
- 2015-07-16 JP JP2017502894A patent/JP2017520612A/ja active Pending
- 2015-07-16 AU AU2015227454A patent/AU2015227454B2/en not_active Ceased
- 2015-07-16 CN CN201580038838.2A patent/CN106661005A/zh active Pending
- 2015-07-16 RU RU2017104856A patent/RU2017104856A/ru unknown
-
2016
- 2016-01-29 AU AU2016200541A patent/AU2016200541A1/en not_active Abandoned
- 2016-12-23 PH PH12016502607A patent/PH12016502607A1/en unknown
-
2017
- 2017-01-04 CO CONC2017/0000065A patent/CO2017000065A2/es unknown
- 2017-01-09 CL CL2017000054A patent/CL2017000054A1/es unknown
- 2017-01-11 IL IL250074A patent/IL250074A0/en unknown
- 2017-11-01 AU AU2017254894A patent/AU2017254894A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2017000054A1 (es) | 2017-06-23 |
RU2017104856A (ru) | 2018-08-16 |
AU2016200541A1 (en) | 2016-02-18 |
CN106661005A (zh) | 2017-05-10 |
EP3169683A1 (en) | 2017-05-24 |
KR20170031097A (ko) | 2017-03-20 |
CO2017000065A2 (es) | 2017-05-19 |
AU2015227454B2 (en) | 2016-02-25 |
PH12016502607A1 (en) | 2017-04-24 |
WO2016008011A1 (en) | 2016-01-21 |
IL250074A0 (en) | 2017-03-30 |
EP3169683A4 (en) | 2017-11-22 |
CA2952557A1 (en) | 2016-01-21 |
JP2017520612A (ja) | 2017-07-27 |
AU2017254894A1 (en) | 2017-11-23 |
US20170152226A1 (en) | 2017-06-01 |
BR112017000714A2 (pt) | 2018-01-09 |
AU2015227454A1 (en) | 2016-02-04 |
SG11201610195UA (en) | 2017-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502607A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
PH12016500967A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
ZA201700737B (en) | Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer | |
PH12016501898B1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
IL247845A0 (en) | Antibody preparations to treat cancer | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
EA201791208A1 (ru) | Антитела к cd38 для лечения острого миелолейкоза | |
MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
EA201790173A1 (ru) | Антитела, связывающие axl | |
BR112018015836A2 (pt) | administração de células t engenheiradas para tratamento de cânceres no sistema nervoso central | |
EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
MX2017008456A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
PH12016501422B1 (en) | Functionalised benzopyran compounds and use thereof | |
PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
BR112017022022A8 (pt) | Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas) | |
PH12016501393B1 (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
MX2017009608A (es) | Compuestos anticancerigenos. | |
IN2014DE00883A (es) | ||
GB2546703A (en) | Compounds |